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Introduction Methods Results
• Metastasis is a serious threat to cancer patients, as it 
is one of the major causes of all cancer deaths. 
• Genetic screening in mice and subsequent testing 
has identified Med4, a subunit of the Mediator 
complex, as a dormancy enforcer, or repressor of 
metastatic reactivation. The Mediator complex is a 
multiprotein coactivator that regulates RNA 
polymerase II-related transcription. 
• Interestingly, cancer patient dataset analyses 
indicate that lower levels of Med4 correlate with 
poorer outcomes. Med4 also has significantly 
reduced expression in breast cancer cells. 
• However, the specific role that Med4 plays in 
enforcing dormancy and the mechanisms of 
metastasis upon Med4 deregulation remain to be 
elucidated.
• Lentiviruses are useful carriers of vectors 
containing the shRNA sequence and allow for 
efficient knockdown of genes in mammalian cells. 
Lentiviruses can integrate their genome into the 




I silenced Med4 in dormant breast cancer cells by 
cloning microRNA-E-based (miR-E) short hairpin 
Med4 (shMed4) into lentiviral vectors and 
transducing the cells.
This approach allows for the investigation of the 
mechanisms of metastatic reactivation and how 
Med4 enforces dormancy.
• Short hairpin RNA (shRNA) 
is an engineered RNA 
molecule that silences a 
specific gene via RNA 
interference. 
• microRNA-adapted 





Fig 2: miR-E shRNA. The guide strand that binds 
to the target mRNA is highlighted in yellow. 
Adapted from Fellmann et al.
molecule, allowing it to be expressed by Pol-II 
promoters and processed by the endogenous 
miRNA pathways. The processed shRNA then binds 
to the target mRNA and induces mRNA degradation 
or suppresses translation of that gene, silencing it.
• Utilizing this miRNA pathway leads to less toxicity, 
more precise processing of shRNA, and the ability to 
transcribe several shRNA’s/reporter genes under one 
promoter, as compared to simple stem-loop shRNA. 
Fig 3: Overview of Methods. DNA template containing shMed4 sequence was cloned into 
the lentiviral vector, stable dormant breast cancer cell lines were generated with the lentiviral 
vector incorporated into the genome, and knockdown efficiency was validated.
Results
Fig 1: DNA Construct for Lentiviral Vector. SFFV and PGK are Pol-II promoters. 
Crimson is a reporter protein for miR-E-based shMed4, which has XhoI and EcoRI 
restriction sites, and Neomycin is a marker gene for antibiotic resistance.
Conclusion
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Fig 4: Agarose gels to confirm successful PCR of DNA template and vector 
purification. Left: Digested PCR product of DNA template on 2% agarose gel. The 
digested product is at the expected size for all samples, a little over 100 bp. Right: 
Digested and uncut vector containing DNA template on 1% agarose gel after maxiprep and 
subsequent isolation in preparation for transformation into E. coli cells. The digested 
vectors for both shMed4 #1 and shMed4 #4 are linear and around the expected size, 
between 10 kb and 20 kb. As expected, the uncut vectors for shMed4 #1 and shMed4 #4 
contain a nicked, circular vector and supercoiled vector, without any single-stranded, 
circular vector present.
Fig 5: Fluorescence-activated cell sorting based on Crimson and Green Fluorescent 
Protein (GFP) expression. Crimson signals for shMed4 expression and GFP is linked to 
luciferase for in vivo imaging of metastasis. Cells with the highest Crimson and GFP signals 
were sorted and tested for validation of shMed4 knockdown efficiency.
Fig 6: Fluorescence microscopy images. Crimson and GFP fluorescence was detected 
within the cells.
Fig 8: Validating knockdown efficiency with 
Western Blot Analysis. Decreased amounts of 
Med4 protein were detected for shMed4 #1 and 
#4 compared to NTC. shMed4 #1 and #4 had 
increased protein levels for α-SMA (actin). 
RhoGDI levels were similar for all samples.
• Silencing of Med4 using this DNA construct was 
successful based on the qRT-PCR and Western Blot 
results.
• This knockdown method can allow for additional 
studies that explore the interactions and signaling 
pathways related to Med4 and metastatic 
reactivation. 
• Further investigation can include RNA-sequencing, 
immunofluorescence staining, drug treatment, and 
co-knockdown of genes. 
• Understanding the mechanisms through which 
depletion of Med4 promotes metastatic relapse may 
lead to the identification of novel biomarkers and 
therapies that may benefit a substantial fraction of 
breast cancer patients.
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Fig 7: Validating knockdown efficiency with Real-Time Quantitative Reverse 
Transcription PCR (qRT-PCR). Decreased Med4 mRNA levels were seen for shMed4#1 
and shMed4 #4 compared to NTC. shMed4 #1 and #4 had increased Acta2 and My19 (actin) 
mRNA levels. Gapdh mRNA levels were similar for all samples. * = p-value < 0.05, ** = p-
value < 0.01, *** = p-value < 0.001.
